465 filings
10-Q
2024 Q1
ABBV
Abbvie Inc
Quarterly report
3 May 24
11:04am
8-K
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
8-K
ABBV
Abbvie Inc
3 Apr 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:06pm
PX14A6G
Chevedden John
26 Mar 24
Letter to shareholders
2:31pm
ARS
2023 FY
ABBV
Abbvie Inc
18 Mar 24
Annual report to shareholders
4:27pm
DEFA14A
ebkklj1yu0lpuqq
18 Mar 24
Additional proxy soliciting materials
4:17pm
8-K
1dhjrqa 35lx9up2dj
26 Feb 24
Other Events
5:08pm
424B5
gvin pjlr9
26 Feb 24
Prospectus supplement for primary offering
6:12am
FWP
sxg8e bj07bqn0631j
22 Feb 24
Free writing prospectus
9:14pm
S-8
sxhq31
22 Feb 24
Registration of securities for employees
5:50pm
424B5
b941fo7eekgp
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
f5kd5cdxjmwb
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
2uaks0rb63z 81cub0
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
llp45l0fzn0q2685
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
dn1u76g73iely2etm
5 Jan 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:03pm
8-K
cxyltn
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
6qg2p6l3
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am